Die gleichzeitige Gabe von Darunavir und Ritonavir mit Arzneimitteln, die primär über CYP3A4 metabolisiert werden, kann zu ###>Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A4 may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.